Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr U'Prichard joins Ocimum's board

This article was originally published in Scrip

Executive Summary

David U'Prichard, president of Druid Consulting LLC, has joined the board of Ocimum Biosolutions, a genomics solutions company in India. Dr U'Prichard holds board positions in several companies including Life Technologies, Oxagen, Cyclacel and Silence Therapeutics. He is also a partner at Red Abbey Venture Partners, and was chairman of R&D at SmithKline Beecham from 1997 to 1999, among other senior positions he has held in prior stints in the industry.

You may also be interested in...



Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

As Belviq Goes Off India Market, Patent Case May Fizzle

Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.

Mylan Gets Expert Panel Go-Ahead For Pretomanid In India

Tuberculosis drug pretomanid gets endorsement, with Phase III trial waiver, from a key expert panel that advises India's drugs regulator, but roll out plan needs to be defined under the country’s national TB program, say health activists.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007243

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel